CSIMarket Company Name, Ticker, Competitors, else..
 
Fulcrum Therapeutics Inc   (NASDAQ: FULC)
Other Ticker:  
 
 
Price: $4.2700 $0.22 5.432%
Day's High: $4.39 Week Perf: 11.49 %
Day's Low: $ 3.95 30 Day Perf: 28.61 %
Volume (M): 832 52 Wk High: $ 13.70
Volume (M$): $ 3,551 52 Wk Avg: $6.99
Open: $4.08 52 Wk Low: $2.86



 Market Capitalization (Millions $) 266
 Shares Outstanding (Millions) 62
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) 43
 Capital Exp. (TTM) (Millions $) 0

Fulcrum Therapeutics Inc
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing small molecule therapies to treat genetically defined diseases. The company specializes in identifying and targeting key regulatory control points within cells to restore essential gene control mechanisms. Fulcrum Therapeutics aims to address the root causes of diseases such as neurodevelopmental disorders, rare diseases, and genetic muscular disorders. The company utilizes its proprietary product engine to identify potential drug candidates and advance them through preclinical and clinical development.


   Company Address: 26 Landsdowne Street Cambridge 2139 MA
   Company Phone Number: 651-8851   Stock Exchange / Ticker: NASDAQ FULC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        0.93% 
BGNE   -8.57%    
BMY   -5.7%    
PFE   -1.76%    
REGN   -2.17%    
VRTX        1.82% 
• View Complete Report
   



Announcement

Legal Storm Looms Over Fulcrum Therapeutics Investor Alert Amid Ongoing Investigation,

Published Wed, Sep 25 2024 8:00 PM UTC

Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a prominent player in the biopharmaceutical industry, is currently under investigation by Bronstein, Gewirtz & Grossman, LLC. This development has sent ripples of concern through the investor community, with many seeking to understand the underlying causes and potential implications of this scrutiny.Bronstein, Gewirtz & Grossman, LL...
Announcement

Investigative Inquiry into Fulcrum Therapeutics Implications for Investors and the Pharmaceutical Landscape

Published Thu, Sep 19 2024 8:00 PM UTC

Abstract: The pharmaceutical sector is often characterized by rapid fluctuations in stock prices, driven by a multitude of factors including clinical trial outcomes, regulatory developments, and market dynamics. Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a company focused on advancing precision medicine for patients with genetically-driven diseases, has recently become the s...
Announcement

Investor Alert Bronstein, Gewirtz & Grossman, LLC Initiates Investigation into Fulcrum Therapeutics - Investors...

Published Fri, Sep 13 2024 8:00 PM UTC

NEW YORK, Sept. 13, 2024 Investors holding securities of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) should be aware of an important development. Bronstein, Gewirtz & Grossman, LLC, a renowned law firm specializing in securities litigation, has announced an investigation into potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. Details of the Investigatio...
Management Announcement

Fulcrum Therapeutics? Phase 3 REACH Trial of Losmapimod Shows No Improvement for FSHD Patients; Financial Challenges Emerge Amid Stock Option Grantsnn,

Published Thu, Sep 12 2024 10:55 AM UTC

nnFulcrum Therapeutics Reports Disappointing Phase 3 Results for Losmapimod in FSHD: Financial Ramifications and Stock Performance Analysisnn
Fulcrum Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for rare genetic disorders, recently disclosed top-line results from its Phase 3 REACH clinical trial assessing the e...
Shares

Fulcrum Therapeutics Grants Stock Options to New Employees, Impact on Shareholders Analyzed

Published Fri, Aug 23 2024 8:30 PM UTC



Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company dedicated to developing small molecules for patients with rare genetic diseases, recently announced the granting of non-statutory stock options to two new employees. These stock options, which allow the purchase of shares in the company s common stock, were awarded as part of the ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com